Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03682367 · ClinicalTrials.gov registry record · Phase 3
Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery
A Phase 3 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT03682367 is a Phase 3 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 8 participants.
The verdict
NCT03682367, a Phase 3 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
Patients undergoing head and neck cancer surgery often have a lot of pain after surgery, which can lead to a need for a lot of narcotic pain medication. These medications can have many side effects that can make recovery more difficult including nausea, vomiting, dizziness, being overly sleepy, itchiness, inability to urinate, confusion, inability to have a bowel movement, longer time before being able to start walking. These side effects can make the hospital stay longer. The use of gabapentin, which is a non narcotic pain medication that focuses on nerve pain, has been used in smaller head and neck surgeries including removal of tonsils, sinus surgery, thyroid surgery. Studies in patients needing orthopedic or OB/Gyn surgery have shown improved pain control with gabapentin. Potential benefits to future patients include improved pain control, less narcotic associated side effects and faster functional recovery.
Interventions
- DRUG Gabapentin
- DRUG Placebo - Concentrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2020-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03682367
The ClinicalTrials.gov registry entry for NCT03682367 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gabapentin is the first listed.
NCT03682367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03682367 about?
NCT03682367 is a clinical study titled "Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery". Patients undergoing head and neck cancer surgery often have a lot of pain after surgery, which can lead to a need for a lot of narcotic pain medication. These medications can have many side effects that can make recovery more difficult including nausea, vomiting, dizziness, being overly sleepy, itch...
What is the current status of trial NCT03682367?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2018-12-01. Estimated completion is 2020-04-06.
What interventions are being tested in trial NCT03682367?
The interventions under investigation include: Gabapentin (DRUG), Placebo - Concentrate (DRUG).
Who is sponsoring clinical trial NCT03682367?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.